Radioiodine Therapy of Benign Thyroid Diseases: Graves’ Disease, Plummer’s Disease, Non-toxic Goiter and Nodules



Thyroid diseases are common in all parts of the world. Hormonal disorders of thyroid gland negatively affect whole metabolism, and cause various health problems while goiter and nodules can cause local, compressive symptoms. Once a correct diagnosis is made, a definitive treatment protocol should be initiated. Medications, surgery, and radioactive iodine are currently the most widely available options. Each treatment option has its own advantages, disadvantages, and limitations. This chapter focuses on the role of radioiodine therapy of benign thyroid diseases. Pertinent information is also provided on the basics of thyroid diseases, thyroid medication, and surgery.


Thyroid Stimulate Hormone Thyroid Stimulate Hormone Level Subclinical Hyperthyroidism Radioiodine Uptake Benign Thyroid Disease 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



The authors would like to acknowledge the technical assistance of Arda Dora Aktolun in improving the quality of images and preparing them for publication using his excellent computer skills.


  1. 1.
    Trepacz PT, McCue M, Klein I, Levey GS, Greenhouse J. A psychiatric and neuropsychological study of patients with untreated Graves’ disease. Gen Hosp Psychiatry. 1988;10:49–55.CrossRefGoogle Scholar
  2. 2.
    Trepacz PT, Klein I, Roberts M, Greenhouse J, Levey GS. Graves’ disease: an analysis of thyroid hormone levels and hyperthyroid signs and symptoms. Am J Med. 1989;87:558–61.CrossRefGoogle Scholar
  3. 3.
    Bahn RS, Burch HS, Cooper DS, Garber JR, Greenlee CM, Klein IL, et al. The role of propylthiouracil in the management of Graves’ disease in adults: report of a meeting jointly sponsored by the American Thyroid Association and Food and Drug Administration. Thyroid. 2009;19:673–4.PubMedCrossRefGoogle Scholar
  4. 4.
    Sosa JA, Bowman HM, Tielsch JM, Powe NR, Gordon TA, Udelsman R. The importance of surgeon experience for clinical and economic outcomes from thyroidectomy. Ann Surg. 1998;228:320–30.PubMedCrossRefGoogle Scholar
  5. 5.
    Röher HD, Goretzki PE, Hellman P, Witte J. Complications in thyroid surgery. Incidence and therapy. Chirurg. 1999;70:999–1000.PubMedCrossRefGoogle Scholar
  6. 6.
    Sywak MS, Palazzo FF, Yeh M, Wilkinson M, Snook K, Sidhu SB, et al. Parathyroid hormone assay predicts hypocalcemia after total thyroidectomy. ANZ J Surg. 2007;77:667–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Abbas G, Dubner S, Heller KS. Re-operation for bleeding after total thyroidectomy and parathyroidectomy. Head Neck. 2001;23:544–6.PubMedCrossRefGoogle Scholar
  8. 8.
    Jenkins K, Baker AB. Consent and anaesthetic risk. Anaesthesia. 2003;58:962–84.PubMedCrossRefGoogle Scholar
  9. 9.
    Kraimps JL, Bouin-Pineau MH, Mathonnet M, De Calan L, Ronceray J, Visset J, et al. Multicenter study of thyroid nodules in patients with Graves’ disease. Br J Surg. 2000;87:1111–3.PubMedCrossRefGoogle Scholar
  10. 10.
    Gorman CA. Radioiodine therapy does not aggravate Graves’ ophthalmopathy. J Clin Endocrinol Metab. 1995;80:340–2.PubMedGoogle Scholar
  11. 11.
    Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves’ disease is radioiodine. J Clin Endocrinol Metab. 2007;92:797–800.PubMedCrossRefGoogle Scholar
  12. 12.
    Vitti P, Ragio T, Chiovato L, Pallini S, Santini F, Fiore E, et al. Clinical features of patients with Graves’ disease undergoing remission after antithyroid drug treatment. Thyroid. 1997;7:369–75.PubMedCrossRefGoogle Scholar
  13. 13.
    Erickson D, Gharib H, Li H, van Heerden JA. Treatment of patients with toxic multinodular goiter. Thyroid. 1998;8:277–82.PubMedCrossRefGoogle Scholar
  14. 14.
    Nygaard B, Hegedüs L, Ulriksen P, Nielsen KG, Hansen JM. Radioiodine therapy for multinodular toxic goiter. Arch Intern Med. 1999;159:1364–8.PubMedCrossRefGoogle Scholar
  15. 15.
    Kang AS, Grant CS, Thompson GB, van Heerden JA. Current treatment of nodular goiter with hyperthyroidism (Plummer’s disease): surgery versus radioiodine. Surgery. 2002;132:916–23.PubMedCrossRefGoogle Scholar
  16. 16.
    Vidal-Trecan GM, Stahl JE, Eckman MH. Radioiodine or surgery for toxic thyroid adenoma: dissecting an important decision. A cost-effective analysis. Thyroid. 2004;14:933–45.PubMedCrossRefGoogle Scholar
  17. 17.
    Pappalardo G, Guadalaxara A, Frattaroli FM, Illomei G, Falaschi P. Total compared with subtotal thyroidectomy in benign nodular disease: personal series and review of published reports. Eur J Surg. 1998;164:501–6.PubMedCrossRefGoogle Scholar
  18. 18.
    Thomusch O, Machens A, Sekula C, Ukkat J, Lippert H, Gastinger I, et al. Multivariate analysis of risk factors for postoperative complications in benign goiter surgery: prospective multicenter study in Germany. World J Surg. 2000;24:1335–41.PubMedCrossRefGoogle Scholar
  19. 19.
    Hisham AN, Azlina AF, Aina EN, Sarojah A. Total thyroidectomy: the procedure of choice for multinodular goiter. Eur J Surg. 2001;167:403–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Albino CC, Graf H, Sampaio AP, Vigario A, Paz-Filho GJ. Thiamazole as an adjuvant to radioiodine for volume reduction of multinodular goiter. Expert Opin Investig Drugs. 2008;17:1781–6.PubMedCrossRefGoogle Scholar
  21. 21.
    Regalbuto C, Salamone S, Scollo C, Vigneri R, Pezzino V. Appearance of anti-TSH receptor antibodies and clinical Graves’ disease after radioiodine ­therapy for hyperfunctioning thyroid adenoma. J Endocrinol Invest. 1999;22:147–50.PubMedGoogle Scholar
  22. 22.
    Kendall-Taylor P, Keir M, Ross WM. Ablative radioiodine therapy for hyperthyroidism: long term follow-up study. Br Med J. 1984;289:361–3.CrossRefGoogle Scholar
  23. 23.
    Reiners C. Functional autonomy of the thyroid: ­volume reduction after radioiodine treatment. Exp Clin Endocrinol. 1993;101:136–8.Google Scholar
  24. 24.
    Kinser JA, Roesler H, Furrer T, Grütter D, Zimmerman H. Nonimmunogenic hyperthyroidism: cumulative hypothyroidism incidence after radioiodine and surgical treatment. J Nucl Med. 1989;30:1960–5.PubMedGoogle Scholar
  25. 25.
    Ceccarelli C, Bencivelli W, Vitti P, Grasso L, Pinchera A. Outcome of radioiodine-131 therapy in hyperfunctioning thyroid nodules: a 20-years’ retrospective study. Clin Endocrinol (Oxf). 2005;62:331–5.CrossRefGoogle Scholar
  26. 26.
    Kahraman D, Keller C, Schneider C, Eschner W, Sudbrock F, Schbrsmidt M, et al. Development of hypothyroidism during long term follow-up of patients with toxic nodular goiter after radioiodine therapy. Clin Endocrinol (Oxf). 2012;76:297–303.CrossRefGoogle Scholar
  27. 27.
    Manders JMB, Corstens FHM. Radioiodine therapy of euthyroid multinodular goiters. Eur J Nucl Med. 2002;29:466–70.CrossRefGoogle Scholar
  28. 28.
    Kaniuka S, Lass P, Sworczak K. Radioiodine-an attractive alternative to surgery in large non-toxic multinodular goiters. Nucl Med Rev Cent East Eur. 2009;12:23–9.PubMedGoogle Scholar
  29. 29.
    Ceccarelli C, Brozzi F, Bianchi F, Santini P. Role of recombinant human TSH in the management of large euthyroid multinodular goiter: a new therapeutic option? Pros and cons. Minerva Endocrinol. 2010;35:161–71.PubMedGoogle Scholar
  30. 30.
    Braverman L, Kloos RT, Law Jr B, Kipnes M, Dionne M, Magner J. Evaluation of various doses of recombinant human thyrotropin in patients with multinodular goiters. Endocr Pract. 2008;14:832–9.PubMedGoogle Scholar
  31. 31.
    Baczyk M, Pisarek M, Czepczyński R, Ziemnicka K, Gryczyńska M, Pietz L, et al. Therapy of large multinodular goiter using repeated doses of radioiodine. Nucl Med Commun. 2009;30:226–31.PubMedCrossRefGoogle Scholar
  32. 32.
    Bahn RS, Burch HB, Cooper DS, Garber JR, Greenlee MC, Klein I, et al. Hyperthyroidism and other causes of thyrotoxicosis: management guidelines of American Thyroid Association and American Association of Clinical Endocrinologists. Thyroid. 2011;21:593–646.CrossRefGoogle Scholar
  33. 33.
    Sabri O, Zimny M, Schulz G, Schreckenberger M, Reinartz P, Willmes K, et al. Success rate of radioiodine therapy in Graves’ disease: influence of thyrostatic medication. J Clin Endocrinol Metab. 1999;84:1229–33.PubMedCrossRefGoogle Scholar
  34. 34.
    Andrade VA, Gross JL, Maia AL. The effect of methimazole pretreatment on the efficacy of radioactive iodine therapy in Graves’ hyperthyroidism: one-year follow-up of a prospective, randomized study. J Clin Endocrinol Metab. 2001;86:3488–93.PubMedCrossRefGoogle Scholar
  35. 35.
    Walter MA, Briel M, Christ-Crain M, Bonnema SJ, Connel J, Cooper DS, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomized controlled trials. BMJ. 2007;334:514.PubMedCrossRefGoogle Scholar
  36. 36.
    Bockish A, Jamitzky T, Derwenz R, Biersack HJ. Optimized dose planning of radioiodine therapy of benign thyroidal diseases. J Nucl Med. 1993;34:1632–8.Google Scholar
  37. 37.
    Peters H, Fischer C, Bogner U, Rainers C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard versus calculated 131-iodine activity. Results from a prospective, randomized, multicentric study. Eur J Clin Invest. 1995;25:186–93.PubMedCrossRefGoogle Scholar
  38. 38.
    de Rooij A, Vandenbroucke JP, Smit JW, Stokkel MP, Dekkers OM. Clinical outcomes after estimated versus calculated activity of radioiodine for the treatment of hyperthyroidism: systematic review and meta-­analysis. Eur J Endocrinol. 2009;161:771–7.PubMedCrossRefGoogle Scholar
  39. 39.
    Salvatori M, Luster M. Radioiodine dosimetry in benign thyroid disease and differentiated thyroid carcinoma. Eur J Nucl Med Mol Imaging. 2010;37:821–8.PubMedCrossRefGoogle Scholar
  40. 40.
    Merrill S, Horowitz J, Traino AC, Chipkin SR, Hollot CV, Chait Y. Accuracy and optimal timing of activity measurements in estimating the absorbed dose of radioiodine in the treatment of Graves’ disease. Phys Med Biol. 2011;56:557–71.PubMedCrossRefGoogle Scholar
  41. 41.
    Liu CJ, Dong YY, Wang YW, Wang KH, Zeng QY. Efficiency analysis of using tailored individual doses of radioiodine and fine tuning using a low-dose antithyroid drugs in the treatment of Graves’ disease. Nucl Med Commun. 2011;32:227–32.PubMedCrossRefGoogle Scholar
  42. 42.
    Magner J. Problems associated with the use of thyrogen in patients with a thyroid gland. N Engl J Med. 2008;359:1738–9.PubMedCrossRefGoogle Scholar
  43. 43.
    Zakavi SR, Mousavi Z, Davachi B. Comparison of four different protocols of I-131 therapy for treating single toxic thyroid nodule. Nucl Med Commun. 2009;30:169–75.PubMedCrossRefGoogle Scholar
  44. 44.
    Bonnema SJ, Nielsen VE, Hegedüs L. Radioiodine therapy in non-toxic multinodular goiter. The possibility of effect-amplification with recombinant human TSH (rhTSH). Acta Oncol. 2006;45:1051–8.PubMedCrossRefGoogle Scholar
  45. 45.
    Fast S, Nielsen VE, Bonnema SJ, Hegedüs L. Time to re-consider non-surgical therapy of benign non-toxic multinodular goiter: focus on recombinant TSH augmented radioiodine therapy. Eur J Endocrinol. 2009;160:517–28.PubMedCrossRefGoogle Scholar
  46. 46.
    Fast S, Bonnema SJ, Hegedüs L. Radioiodine therapy in non-toxic multinodular goiter. Potential role of recombinant human TSH. Ann Endocrinol (Paris). 2011;72:129–35.CrossRefGoogle Scholar
  47. 47.
    Tallstedt L, Lundell G, Torring O, Wallin G, Ljunggren JG, Blomgren H, et al. Occurrence of ophthalmopathy after treatment for Graves’ hyperthyroidism. The Thyroid Study Group. N Eng J Med. 1992;326:1733–8.CrossRefGoogle Scholar
  48. 48.
    Bartalena L, Marcocci C, Bogazzi F, Manetti L, Tanda ML, Dell’Unto E, et al. Relation between therapy for hyperthyroidism and the course of Graves’ ophthalmopathy. N Eng J Med. 1998;338:73–8.CrossRefGoogle Scholar
  49. 49.
    Laurberg P, Walling G, Tallstedt L, Abraham-Nording M, Lundell G, Torring O. TSH-receptor autoimmunity in Graves’ disease after therapy with anti-thyroid drugs, surgery, or radioiodine: a 5-year prospective randomized study. Eur J Endocrinol. 2008;158:69–75.PubMedCrossRefGoogle Scholar
  50. 50.
    Bahn RS. Graves’ ophthalmopathy. N Eng J Med. 2010;362:726–38.CrossRefGoogle Scholar
  51. 51.
    Pfeilschifter J, Ziegler R. Smoking and endocrine ophthalmopathy: impact of smoking severity and current vs lifetime cigarette consumption. Clin Endocrinol (Oxf). 1996;45:477–81.CrossRefGoogle Scholar
  52. 52.
    Regensburg NI, Wiersinga WM, Berendschot TT, Saeed P, Mourits MP. Effect of smoking on orbital fat and muscle volume in Graves’ orbitopathy. Thyroid. 2011;21:177–81.PubMedCrossRefGoogle Scholar
  53. 53.
    De Bellis A, Conzo G, Cennamo G, Pane E, Bellastella G, Colella C, et al. Time course of Graves’ ophthalmopathy after total thyroidectomy alone or followed by radioiodine therapy: a 2-year longitudinal study. Endocrine. 2012;41(2):320–6.PubMedCrossRefGoogle Scholar
  54. 54.
    Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed dose radio-ablation therapy of Graves’ disease in children. J Pediatr. 2002;141:99–103.Google Scholar
  55. 55.
    Rivkees SA, Cernelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics. 2003;111:745–9.Google Scholar
  56. 56.
    Bonnema SJ, Bennedbaek FN, Gram J, Veje A, Marving J, Hegedus L. Resumption of methimazole after I-131 therapy of hyperthyroid diseases: effect on thyroid function and volume evaluated by a randomized clinical trial. Eur J Endocrinol. 2003;149:485–92.PubMedCrossRefGoogle Scholar
  57. 57.
    Dolphin GW. The risk of thyroid cancers following irradiation. Health Phys. 1968;15:219–28.PubMedCrossRefGoogle Scholar
  58. 58.
    Ron E, Lubin JH, Shore RE, Mabuchi K, Modan B, Pottern LM, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res. 1995;141:259–77.PubMedCrossRefGoogle Scholar
  59. 59.
    Boice Jr JD. Radiation and thyroid cancer: what more can be learned? Acta Oncol. 1998;37:321–4.PubMedCrossRefGoogle Scholar
  60. 60.
    Sigurdson AJ, Ronckers CM, Mertens AC, Stovall M, Smith SA, Liu Y, et al. Primary thyroid cancer after a first tumour in childhood (the Childhood Cancer Survivor Study): a nested case-control study. Lancet. 2005;365:2014–23.PubMedCrossRefGoogle Scholar
  61. 61.
    Boice Jr JD. Radiation-induced thyroid cancer—what’s new? J Natl Cancer Inst. 2005;97:703–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Gómez-Arnaiz N, Andía E, Gumà A, Abós R, Soler J, Gómez JM. Ultrasonographic thyroid volume as a reliable prognostic index of radioiodine-131 treatment outcome in Graves’ disease hyperthyroidism. Horm Metab Res. 2003;35:492–7.PubMedCrossRefGoogle Scholar
  63. 63.
    Nakatake N, Fukata S, Tajiri J. Prediction of post-treatment hypothyroidism using changes in thyroid volume after radioactive iodine therapy in adolescent patients with Graves’ disease. Int J Pediatr Endocrinol. 2011;2011:14.PubMedCrossRefGoogle Scholar
  64. 64.
    Carpentier WR, Gilliland PF, Piziak VK, Petty FC, McConnell BG, Verdonk CA, et al. Radioiodine uptake following iodine-131 therapy for Graves’ disease: an early indicator of need for retreatment. Clin Nucl Med. 1989;14:15–8.PubMedCrossRefGoogle Scholar
  65. 65.
    Leslie WD, Peterdy AE, Dupont JO. Radioiodine treatment outcomes in thyroid glands previously irradiated for Graves’ hyperthyroidism. J Nucl Med. 1998;39:712–6.PubMedGoogle Scholar
  66. 66.
    Alexander EK, Larsen PR. High dose of 131-I therapy for the treatment of hyperthyroidism caused by Graves’ disease. J Clin Endocrinol Metab. 2002;87:1073–7.PubMedCrossRefGoogle Scholar
  67. 67.
    Ceccarelli C, Canale D, Battisti P, Caglieresi C, Moschini C, Fiore E, et al. Testicular function after I-131 therapy for hyperthyroidism. Clin Endocrinol (Oxf). 2006;65:446–52.CrossRefGoogle Scholar
  68. 68.
    Baxter MA, Stewart PM, Daykin J, Sheppard MC, Franklyn JA. Radioiodine therapy for hyperthyroidism in young patients-perception of risk and use. Q J Med. 1993;86:495–9.PubMedCrossRefGoogle Scholar
  69. 69.
    Rosário PW, Barroso AL, Rezende LL, Padrão EL, Borges MA, Guimarães VC, et al. Testicular function after radioiodine therapy in patients with thyroid cancer. Thyroid. 2006;16:667–70.PubMedCrossRefGoogle Scholar
  70. 70.
    Holm LE, Lundell G, Israelson A, Dahlqvist I. Incidence of hypothyroidism occurring long after iodine-131 therapy for hyperthyroidism. J Nucl Med. 1982;23:103–7.PubMedGoogle Scholar
  71. 71.
    Goldstein R, Hart IR. Follow-up of solitary autonomous thyroid nodules treated with I-131. N Engl J Med. 1983;309:1473–6.PubMedCrossRefGoogle Scholar
  72. 72.
    Nygaard B, Hegedüs L, Nielsen KG, Ulriksen P, Hansen JM. Long-term effect of radioactive iodine on thyroid function and size in patients with solitary autonomously functioning toxic thyroid nodules. Clin Endocrinol (Oxf). 1999;50:197–202.CrossRefGoogle Scholar
  73. 73.
    Peters H, Fischer C, Bogner U, Rieners C, Schleusener H. Radioiodine therapy of Graves’ hyperthyroidism: standard vs. calculated 131-iodine activity. Results from a prospective, randomized, multicentric study. Eur J Clin Invest. 1995;25:186–93.PubMedCrossRefGoogle Scholar
  74. 74.
    Haase A, Bähre M, Lauer I, Meller B, Richter E. Radioiodine therapy in Graves’ hyperthyroidism: determination of individual optimum target dose. Exp Clin Endocrinol Diabetes. 2000;108:133–7.PubMedCrossRefGoogle Scholar
  75. 75.
    Marinelli LD, Quinby EH, Hine GJ. Dosage determination with radioactive isotopes; practical considerations in therapy and protection. Am J Roentgenol Radium Ther. 1948;59:260–81.PubMedGoogle Scholar
  76. 76.
    Traino AC, Di Martino F, Lazzeri M. A dosimetric approach to patient-specific radioiodine treatment of Graves’ disease with incorporation of treatment-induced changes in thyroid mass. Med Phys. 2004;31:2121–7.PubMedCrossRefGoogle Scholar
  77. 77.
    Catargi B, Leprat F, Guyot M, Valli N, Ducassou D, Tabarin A. Optimized radioiodine therapy of Graves’ disease: analysis of delivered dose and of other possible factors affecting outcome. Eur J Endocrinol. 1999;141:117–21.PubMedCrossRefGoogle Scholar
  78. 78.
    Traino AC, Di Martino F, Lazzeri M, Stabin MG. Study of the correlation between administered activity and radiation committed dose to the thyroid in 131-I therapy of Graves’ disease. Radiat Prot Dosimetry. 2001;95:117–24.PubMedCrossRefGoogle Scholar
  79. 79.
    Traino AC, Xhafa B. Accuracy of two simple methods for estimation of thyroidal 131-I kinetics of for dosimetry-based treatment of Graves’ disease. Med Phys. 2009;36:1212–8.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2013

Authors and Affiliations

  1. 1.Tirocenter Nuclear Medicine CenterIstanbulTurkey
  2. 2.Nuclear Medicine ServiceGATA Haydarpasa Teaching HospitalIstanbulTurkey

Personalised recommendations